Mikhail Blagosklonny is a Passionate Researcher and Innovator

Posted on January 12, 2017

Dr. Mikhail Blagosklonny is a respected professional who specializes in diagnosis and treatment of cancer. He also has interests in the field of gerontology. Dr. Blagosklonny is a professor at the Roswell Park Cancer Institute based in New York.

Educational background and career

Dr. Blagosklonny studied at The First Pavlov State Medical University headquartered in St. Petersburg, Russia. His first degree was in internal medicine, and Ph.D. was in experimental medicine and cardiology. In 2002, he was called upon to serve as an associate professor of medicine at New York Medical College. At this college, he lectures at the department of medicine. The same year, he was also appointed as a senior scientist at Ordway Research Institute of Albany, New York. In April 2009, Dr. Mikhail Blagoskylonny was assigned the role of an oncology professor at the Roswell Park Cancer Institute. He still retained his jobs at Ordway Research Institute and New York Medical College.

Dr. Blagosklonny’s role at Roswell Park Cancer Institute

This institute was established in 1898 by Dr. Roswell Park. Roswell Park Cancer Institute based in New York pioneers in cancer treatment and research on wikipedia.org. The Institute has staff ranging from clinicians and oncologist, postdoctoral research fellows, predoctoral graduates, master’s students, and volunteers. With his vast experience in cancer research, he helps in running the cancer research division of the institute.

Dr. Blagosklonny’s interests and research work
Dr. Mikhail Blagosklonny’s interests are in cancer and cancer therapies as well as aging and development of anti-aging drugs. He also has vested interests in molecular and cellular biology and clinical investigations in signal transduction, cell cycle, and cell senescence. Additionally, he also conducts research in anticancer therapeutics with emphasis on new anticancer drugs.

He has authored over 270 research works such as book chapters, articles, and reviews on tandfonline.com. His journals have over 25,000 citations. Dr. Blagosklonny is the chief editor and founder of Cell Cycle, a weekly scientific journal covering cell biology. Dr. Blagosklonny is also an editor of American Journal of Pathology, International Journal of Cancer, Cell Death and Differentiation, Cancer Biology, and Therapy.

Dr. Blagosklonny’s hypothesis on TOR signaling

In his mission of fighting cancer at https://www.linkedin.com/in/mikhail-blagosklonny-91abb531, Dr. Blagosklonny has come up with a new postulate on the role of TOR signaling in cancer and aging. He proposed the use of rapamycin in antiaging research. Rapamycin is a common drug used in the treatment of lung cancer. He is well-known across the globe for his efforts to develop effective cancer treatment medications.